Events
47 results
Applied filters
SMRs in problematic polypharmacy: antimicrobial focus
12 May 2026Expert pharmacists used case studies to illustrate a patient centred approach to SMRs for patients on antimicrobials.
Stability challenges in aseptic services
26 June 2026An SPS Quality Assurance (QA) bite size learning event on evaluating chemical and physical stability of medicines prepared in pharmacy aseptic services.
Primary care discussions: HRT use in clinical practice
24 April 2024This ‘on the couch’ webinar, the second in a series of two, addressed questions around the challenges faced by pharmacists with HRT decision making.
SMRs in problematic polypharmacy: insomnia focus
14 April 2026Expert pharmacists used a case study to illustrate a patient centred and holistic approach to SMRs for patients prescribed medicines for insomnia.
Sustainability in aseptic services
26 March 2026An SPS Quality Assurance (QA) bite size learning event on sustainability in aseptic services.
Biosimilars and key generic medicines - March 2026 update
18 March 2026An update about biosimilar and key generic medicines to support system planning and mobilisation.
SMRs in problematic polypharmacy: cardiovascular disease focus
10 March 2026Consultant pharmacists used a case study to illustrate a patient centred approach to SMRs for patients with cardiovascular disease.
Updated clinical trials regulation: implementation considerations
26 February 2026An SPS Quality Assurance learning event on understanding the updated clinical trials regulation and practical considerations for pharmacy clinical trials sites.
Personalising evidence-based medicine to reduce polypharmacy
11 February 2025An insight on principles of patient centred structured medication reviews; using the current evidence and shared decision making to facilitate de-prescribing.
Personalised evidence-based medicine to minimise polypharmacy
4 March 2025A consultant pharmacist used case studies to illustrate a patient-centered approach to deprescribing in patients with problematic polypharmacy.